Meeting
2015 ASCO Annual Meeting
First-in-human phase I trial of the PI3Kb-selective inhibitor SAR260301 in patients with advanced solid tumors (NCT01673737).
Authors
Philippe L. Bedard
Princess Margaret Cancer Centre, Toronto, ON, Canada
Philippe L. Bedard , Michael A. Davies , Scott Kopetz , Keith T. Flaherty , Geoffrey Shapiro , Jason John Luke , Anna Spreafico , Bin Wu , Corinne Gomez , Sylvaine Cartot-Cotton , Florent Mazuir , Sandrine Micallef , Brigitte Demers , Dejan Juric
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Pharmacology
Clinical Trial Registration Number
NCT01673737
Citation
J Clin Oncol 33, 2015 (suppl; abstr 2564)
DOI
10.1200/jco.2015.33.15_suppl.2564
Abstract #
2564
Poster Bd #
280
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
A phase I, first-in-human dose study of the dual PI3K/mTOR inhibitor LY3023414 (LY) in patients (pts) with advanced cancer.
First Author: Kathleen N. Moore
Poster
2011 ASCO Annual Meeting
A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors.
First Author: A. J. Wagner
Poster
2024 ASCO Annual Meeting
First-in-human study of RLY-2608, a pan-mutant and isoform selective PI3Kα inhibitor, as a single agent in patients (pts) with advanced solid tumors and in combination with fulvestrant in pts with advanced breast cancer.
First Author: Cristina Saura
Poster
2021 ASCO Annual Meeting
Preliminary efficacy from an ongoing phase 1 dose escalation study of seclidemstat (SP-2577) in patients (pts) with advanced solid tumors (AST).
First Author: Sant P. Chawla